Ambrx | protein therapeutics - antibody drug conjugates

A Convergence of Chemistry And Biology To Create Better Medicine

Learn More

WHAT WE BELIEVE

Ambrx is developing innovative protein therapeutics that preserve potency, reduce dosing frequency and improve homogeneity of the drug substance.

Learn More

Our Technology

Ambrx is harnessing the power of an expanded genetic code to optimize the performance of therapeutic proteins, peptides, bi-specifics and full length antibody conjugates

Learn More

PIPELINE

Ambrx has a number of highly differentiated product candidates at various stages of development in its pipeline, with a focus on “best in class” biopharmaceutical product opportunities.

Learn More

Partnerships

Partnerships for Next Generation Biologics

Learn More

News

Nov 9, 2020

SAN DIEGO, November 9, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded...

A Convergence of Chemistry And Biology To Create Better Medicine

WHAT WE BELIEVE

Our Technology

PIPELINE

Partnerships

News

Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics

Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics

A Phase 1 Study of ARX788, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Metastatic HER2-Positive Breast Cancer